The basis for current treatment recommendations for malignant gliomas

Journal of Neuro-Oncology

Volumn 20, Issue 2, 1994, Pages 111-120

  Fine, Howard A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

chemotherapy; glioma; radiotherapy

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; HYDROXYUREA; LOMUSTINE; MEPREDNISONE; MITOLACTOL; NITROSOUREA DERIVATIVE; PROCARBAZINE; TIOGUANINE; VINCRISTINE;

ARTICLE; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; META ANALYSIS; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BRAIN NEOPLASMS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; PROGNOSIS; RADIOTHERAPY DOSAGE; STATISTICS;

EID: 0028075307     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/BF01052722     Document Type: Article

References (68)

1. Epidemiology of brain tumors: The national survey of intracranial neoplasm
2. Classification and incidence of neoplasms of the central nervous system
3. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastoma and anaplastic astrocytomas
4. The management of malignant gliomas with radiation therapy: therapeutic results and research strategies
5. The role of chemotherapy in the treatment of gliomas in adults
6. Theory and practice of clinical trials
7. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immunotherapy. One hundred thirty-three randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
8. Evaluation of prognostic factors in chemotherapy of recurrent brain tumors
9. Necrosis as a prognostic criterion in malignant supratentorial astrocytic gliomas
10. Survival and prognosis of patients with astrocytomas with atypical or anaplastic features
11. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma
12. Comparison of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma
13. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant gliomas
14. Radiotherapy for high grade gliomas
15. Glioblastoma multiforme and anaplastic astrocytoma
16. Hyperfractionation in malignant glioma report on a dose searching phase I/II protocol of the Radiation Therapy Oncology Group (RTOG)
17. Prognostic factors for high grade gliomas: Development of a prognostic index
18. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme
19. Prognostic factors for malignant glioma
20. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study
21. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade gliomas
22. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumor
23. Response criteria for Phase II studies of supratentorial malignant glioma
24. Influence of measurement error on assessment of response to anticancer chemotherapy: Proposal for new criteria of tumor response
25. The accuracy of volumetric measurement of high-grade gliomas
26. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time. A prospective multicenter trial of the Scandinavian Glioblastoma Study Group
27. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas
28. An analysis of doseeffect relationship in the radiotherapy of malignant gliomas
29. High dose radiation therapy in the treatment of malignant gliomas
30. A Medical Research Council Trial of two radiotherapy doses in the treatment of grade 3 and 4 astrocytoma
31. Combined modality approach to treatment of malignant gliomas: Reevaluation of RTOG 7401/ECOG 1374 with long-term followup
32. Radiation therapy for neoplasm of the brain
33. Assumptions in the radiotherapy of glioblastomas
34. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma
35. Supratentorial malignant glioma: Patterns of recurrence and implications for external beam local treatment
36. Radiotherapy in the treatment of cerebral astrocytomas
37. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma
38. Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas
39. Malignant astrocytoma: Hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial
40. Multiple-fraction-per-day external beam radiotherapy for adults with supratentorial malignant gliomas
41. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma-possible advantage observed at 72 Gy on 1.2 Gy b.i.d. fractions: Report of the Radiation Therapy Oncology Group Protocol 8302
42. High activity iodine-125 interstitial implant for gliomas
43. Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: The UCSF experience
44. Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma
45. Radiosurgery as part of the initial management of patients with malignant gliomas
46. A comparison of radiotherapy alone with radiotherapy and CCNU in cerebral glioma
47. Dianhydrogalactitol and radiation therapy: treatment of supratentorial glioma
48. Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme
49. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant gliomas after surgery
50. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
51. The concept of an overview of cancer clinical trials with emphasis on early breast cancer
52. Phase III comparison of chemotherapy with BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiation therapy with hydroxyurea to patients with malignant gliomas
53. NCOG protocol 6G91: seven-drug chemotherapy and irradiation for patients with glioblastoma multiforme
54. Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report
55. The chemotherapy of brain tumors: clinical experience with carmustine (BCNU) and vincristine
56. BCNU (1.3-bis(2-chloroethyl)-1-nitrosourea: NSC-409962) in the treatment of malignant brain tumora preliminary report
57. 1.3-Bis(2-chloroethyl)-l-nitrosourea) NSC-409962 in the treatment of brain tumors
58. Phase II study of cisplatin in recurrent astrocytomas in adults: a Southwest Oncology Group study
59. Treatment of astrocytoma with a 5-day cisplatin infusion
60. Treatment of recurrent glioma with carboplatin
61. Effect of human leukocyte interferon on malignant brain tumors
62. Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine
63. Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance
64. Successful chemotherapy for recurrent malignant oligodendroglioma
65. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma
66. Phase II study of chemotherapy for anaplastic oligodendroglioma (preliminary report). A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study